Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catharine A Mielnik

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 5, 2020
CB<sub>1</sub> allosteric modulators and their therapeutic potential in CNS disordersCatharine A Mielnik, Vincent M Lam, Ruth A Ross
The Journal of Pharmacology and Experimental Therapeutics|April 18, 2024
The JPET Editorial Fellowship: Opening the Blinds to the Peer Review and Editorial ProcessMayur K Ladumor, Catharine A Mielnik, Cristina D Peterson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2023
Deficits in integrative NMDA receptors caused by Grin1 disruption can be rescued in adulthoodSridevi Venkatesan, Mary A Binko, Catharine A Mielnik, et al.
Cannabis and Cannabinoid Research|October 17, 2022
Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of PsychosisCatharine A Mielnik, Chun Kit Li, Amy J Ramsey, et al.
Schizophrenia Bulletin|January 28, 2017
Postsynaptic Density-95 Isoform Abnormalities in SchizophreniaAdam J Funk, Catharine A Mielnik, Rachael Koene, et al.
Plos One|January 6, 2026
Sex and gender influences on problematic cannabis use and cannabis use disorder: A scoping review protocolJustin Matheson, Catharine A Mielnik, Rodney Knight, et al.
Scientific Reports|March 27, 2019
Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophreniaCourtney R Sullivan, Catharine A Mielnik, Adam Funk, et al.
Frontiers in Pharmacology|September 21, 2018
Behavioral Effects of a Potential Novel TAAR1 AntagonistVincent M Lam, Catharine A Mielnik, Corey Baimel, et al.
The European Journal of Neuroscience|April 24, 2014
Sustained N-methyl-d-aspartate receptor hypofunction remodels the dopamine system and impairs phasic signalingMark J Ferris, Marija Milenkovic, Shuai Liu, et al.
Molecular Neurobiology|October 20, 2018
Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel TreatmentsCourtney R Sullivan, Catharine A Mielnik, Sinead M O'Donovan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 5, 2020
CB<sub>1</sub> allosteric modulators and their therapeutic potential in CNS disordersCatharine A Mielnik, Vincent M Lam, Ruth A Ross
The Journal of Pharmacology and Experimental Therapeutics|April 18, 2024
The JPET Editorial Fellowship: Opening the Blinds to the Peer Review and Editorial ProcessMayur K Ladumor, Catharine A Mielnik, Cristina D Peterson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2023
Deficits in integrative NMDA receptors caused by Grin1 disruption can be rescued in adulthoodSridevi Venkatesan, Mary A Binko, Catharine A Mielnik, et al.
Cannabis and Cannabinoid Research|October 17, 2022
Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of PsychosisCatharine A Mielnik, Chun Kit Li, Amy J Ramsey, et al.
Schizophrenia Bulletin|January 28, 2017
Postsynaptic Density-95 Isoform Abnormalities in SchizophreniaAdam J Funk, Catharine A Mielnik, Rachael Koene, et al.
Plos One|January 6, 2026
Sex and gender influences on problematic cannabis use and cannabis use disorder: A scoping review protocolJustin Matheson, Catharine A Mielnik, Rodney Knight, et al.
Scientific Reports|March 27, 2019
Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophreniaCourtney R Sullivan, Catharine A Mielnik, Adam Funk, et al.
Frontiers in Pharmacology|September 21, 2018
Behavioral Effects of a Potential Novel TAAR1 AntagonistVincent M Lam, Catharine A Mielnik, Corey Baimel, et al.
The European Journal of Neuroscience|April 24, 2014
Sustained N-methyl-d-aspartate receptor hypofunction remodels the dopamine system and impairs phasic signalingMark J Ferris, Marija Milenkovic, Shuai Liu, et al.
Molecular Neurobiology|October 20, 2018
Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel TreatmentsCourtney R Sullivan, Catharine A Mielnik, Sinead M O'Donovan, et al.
Pageof 2